Department of Pediatrics and Child Health

Permanent URI for this collectionhttps://repository.mu.edu.et/handle/123456789/164

Browse

Filter results by typing the first few letters
Now showing 1 - 1 of 1
  • No Thumbnail Available
    Item
    Availability, price, and affordability of anti-cancer medicines in children in Mekelle, Tigray, Ethiopia
    (Mekelle University, 2024-09-01) Teklebirhan Hailu
    Background: Childhood cancer is a significant public health concern, particularly in low and middle-income countries (LMICs). Access to effective anti-cancer medicines is crucial for improving survival rates and quality of life. There is a lack of data on the availability and pricing of anti-cancer medicines for children in LMICs, including Ethiopia. This study aims to evaluate the availability, price, and affordability of anti-cancer medications for children in Mekelle, Tigray, Ethiopia. Methods: The study was cross-sectional using a modified form of the World Health Organization and Health Action international methodology of measuring medicine price, availability, and affordability of childhood anti-cancer drugs in purposeful Ayder Comprehensive Specialized Hospital, purposefully selected 7 private pharmacies, and a RedCross pharmacy found in Mekelle, Tigray, Ethiopia, from April to September 2024. The study includes 24 cytotoxic medications listed in the WHO essential medication list for children and was collected in the form of lowest-priced generics and originator brands from the health sectors found in Mekelle. The data were entered and analyzed using WHO/HAI data entry in a in a Microsoft Excel (V 15.0)-customized program to enter and analyze the data collected and analysis form. Result: The overall availability of anti-cancer medication in all sectors was found to be low (38.45%). The availability of LPGs was 41.7% and 37.49% in the public and private sectors, respectively. Anti-cancer medications were totally unavailable at Red Cross Pharmacy. The median MPR of LPG for the public sector and private sector was 1.293 and 2.8925, respectively. The prices of cytotoxic medications available in the private sector were higher than in the public. All anti-cancer medicines for the treatment of the most common cancers in Mekelle were unaffordable. Conclusion: Medicines for cancer treatment are unavailable, and the few available medicines are unaffordable in Mekelle. Based on this, we recommend subsidies for essential childhood cancer medicines and importation of cancer medicines by the government. Improvement in price transparency, health insurance schemes for childhood cancers to be affordable